OGI vs. CMED, WEED, EMC, ICC, LEAF, MGW, BE, BLO, SL, and MJN
Should you be buying Organigram stock or one of its competitors? The main competitors of Organigram include CanniMed Therapeutics (CMED), Canopy Growth (WEED), Emblem (EMC), ICC Labs (ICC), Leaf Mobile (LEAF), Maple Leaf Green World (MGW), Beleave (BE), Cannabix Technologies (BLO), Supreme Cannabis Company Inc, (SL), and Cronos Group (MJN). These companies are all part of the "cannabis" industry.
Organigram vs.
Organigram (TSE:OGI) and CanniMed Therapeutics (TSE:CMED) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their profitability, media sentiment, institutional ownership, community ranking, risk, valuation, dividends, earnings and analyst recommendations.
CanniMed Therapeutics has lower revenue, but higher earnings than Organigram.
CanniMed Therapeutics has a net margin of 0.00% compared to Organigram's net margin of -153.80%. CanniMed Therapeutics' return on equity of 0.00% beat Organigram's return on equity.
In the previous week, Organigram had 1 more articles in the media than CanniMed Therapeutics. MarketBeat recorded 1 mentions for Organigram and 0 mentions for CanniMed Therapeutics. Organigram's average media sentiment score of 0.00 equaled CanniMed Therapeutics'average media sentiment score.
CanniMed Therapeutics received 108 more outperform votes than Organigram when rated by MarketBeat users. Likewise, 75.85% of users gave CanniMed Therapeutics an outperform vote while only 44.95% of users gave Organigram an outperform vote.
8.4% of Organigram shares are owned by institutional investors. 31.3% of Organigram shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.
Organigram currently has a consensus target price of C$3.43, indicating a potential upside of 51.55%. Given Organigram's stronger consensus rating and higher probable upside, analysts plainly believe Organigram is more favorable than CanniMed Therapeutics.
Summary
Organigram beats CanniMed Therapeutics on 7 of the 12 factors compared between the two stocks.
Get Organigram News Delivered to You Automatically
Sign up to receive the latest news and ratings for OGI and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of TSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Organigram Competitors List
Related Companies and Tools
This page (TSE:OGI) was last updated on 1/21/2025 by MarketBeat.com Staff
